ADHD medication in pregnancy linked to few absolute increased risks
Women with significant attention-deficit/hyperactivity disorder do not need to stop treatment during pregnancy.
Attention-Deficit/Hyperactivity Disorder
Prenatal ADHD treatment linked to neonatal morbidity
Treatment with ADHD medication during pregnancy was associated with a higher risk for neonatal morbidity, especially central nervous system-related disorders such as seizures.
Most adolescents with ADHD have indifferent attitudes toward medication
A majority of study participants also reported that they frequently skip doses of ADHD medication.
Many US adults affected by ADHD not properly treated
There is an unmet need for better treatment to manage symptom burden among US adults with ADHD.
FDA approves Adzenys ER for ADHD treatment
The FDA has approved Adzenys ER extended-release oral suspension ADHD treatment for patients 6 years and older.
Suicide attempt risk not associated with ADHD treatment
There does not appear to be an association between methylphenidate hydrochloride treatment for ADHD and suicide attempts.
FDA to review novel investigational treatment for ADHD
Sunovion has submitted a New Drug Application for dasotraline, a new treatment for ADHD.
FDA approves first generic forms of Strattera for ADHD
The generic forms of Strattera are the first to be approved by the FDA for the treatment of ADHD.
Licorice consumption during pregnancy may be harmful for offspring
Girls whose mothers consumed high amounts of licorice during pregnancy have more advanced pubertal maturation at age 12 years.
ADHD accounts for 6 million annual clinician visits for children
More than 6 million physician visits were made by children between 4 and 17 years of age with ADHD in 2012 to 2013.
- Loading...
Loading...
Next post in ADHD Information Center
Loading... 
Loading...